Addison Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Addison Advisors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-200	Closed	-$55.8K	–	737
2026 Q1	$55.8K	Hold	200	–	–	0.01%	408
2025 Q4	$60.6K	Hold	200	–	–	0.01%	389
2025 Q3	$56.1K	Hold	200	–	–	0.01%	403
2025 Q2	$48.3K	Hold	200	–	–	0.01%	415
2025 Q1	$48.7K	Hold	200	–	–	0.01%	391
2024 Q4	$65.7K	Hold	200	–	–	0.02%	344
2024 Q3	$66.9K	Hold	200	–	–	0.02%	355
2024 Q2	$54.6K	Hold	200	–	–	0.02%	364
2024 Q1	$69.2K	Hold	200	–	–	0.02%	324
2023 Q4	$64.6K	Hold	200	–	–	0.03%	325
2023 Q3	$71.7K	Hold	200	–	–	0.03%	286
2023 Q2	$75.8K	Hold	200	–	–	0.04%	268
2023 Q1	$95.8K	Sell	200 -1	-0.5%	-$468	0.05%	231
2022 Q4	$84.5K	Hold	201	–	–	0.05%	234
2022 Q3	$84K	Hold	201	–	–	0.05%	210
2022 Q2	$99K	Hold	201	–	–	0.06%	192
2022 Q1	$113K	Hold	201	–	–	0.06%	196
2021 Q4	$152K	Buy	201 +1	+0.5%	+$748	0.09%	143
2021 Q3	$149K	Hold	200	–	–	0.12%	103
2021 Q2	$129K	Buy	+200	New	+$122K	0.1%	112
2020 Q4	$117K	Buy	+200	New	+$114K	0.11%	111

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Addison Advisors's BIO Position: Q2 2026 in Review

Addison Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2026, closing a stake of 200 shares — an estimated $55.8K sold.

Addison Advisors first reported a position in BIO in Q4 2020 and held it in 21 quarters. The position peaked at $152K in Q4 2021. 399 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

Addison Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q2 2026 after selling out during the quarter.
Addison Advisors sold 200 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $55.8K.
Addison Advisors first reported a position in Bio-Rad Laboratories Class A in Q4 2020 and held it in 21 quarters.
Addison Advisors's Bio-Rad Laboratories Class A position peaked at $152K in Q4 2021.
399 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Addison Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.